Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 82 | 5,029 | 47% |
| 2020 | 60 | 4,113 | 49% |
| 2021 | 56 | 4,141 | 51% |
| 2022 | 68 | 4,473 | 53% |
| 2023 | 76 | 4,831 | 56% |
| 2024 | 75 | 5,343 | 58% |
| 2025 from claims | – | 5,918 5,431–6,262 | 59% |
| 2026 forecast | – | 6,253 5,502–7,216 | 59% |
| 2027 forecast | – | 6,520 5,573–7,769 | 59% |
| 2028 forecast | – | 6,796 5,670–8,321 | 60% |
| 2029 forecast | – | 7,082 5,785–8,882 | 60% |
| 2030 forecast | – | 7,380 5,912–9,457 | 61% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 41% of the cases CMS names in Pennsylvania; 36 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 17% inpatient hospital, 83% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~6,300 | ~1,000 | ~5,200 |
| 2027 · ~6,500 | ~1,000 | ~5,500 |
| 2028 · ~6,800 | ~1,100 | ~5,700 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 16% (17% in 2025), hospital outpatient about 84% (83% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 82 | 4,973+1.9%/yr | +1.9%/yr | 2.8 | 0% | 7,320 in 2030+6.6%/yr |
| Massachusetts | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.3 | 0% | 4,980 in 2030+8.5%/yr |
| New Jersey | 36 | 2,104+9.9%/yr | +9.9%/yr | 2.0 | 0% | 4,020 in 2030+11%/yr |
| Connecticut | 12 | 1,083+3.5%/yr | +3.5%/yr | 3.3 | 0% | 2,100 in 2030+12%/yr |
| New Hampshire | 8 | 422+0.3%/yr | +0.3%/yr | 1.9 | 0% | 790 in 2030+11%/yr |
| Maine | 3 | 224−7.6%/yr | −7.6%/yr | 1.4 | 0% | 320 in 2030+6.4%/yr |
| Vermont | 4 | 192+6.8%/yr | +6.8%/yr | 1.7 | 0% | 560 in 2030+20%/yr |
| Rhode Island | 4 | 147+4.9%/yr | +4.9%/yr | 1.6 | 0% | 310 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 915 | 164,346−1.8%/yr | −1.8%/yr | 125.51.0× | 44% | 166,800 in 2030+0.2%/yr |
| ERCP & endoscopic ultrasound | 86 | 5,501−2.6%/yr | −2.6%/yr | 4.11.2× | 1% | 6,190 in 2030+2%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Capsovision leads with 22% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 22 companies reported engagement with Pennsylvania’s surgeons worth $371K in consulting, speaking, meals and travel tied to these products, about $4,953 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.